Will you live to 120? · The Hunger Switch

The most oversold molecule

What about humans? We can’t ethically run a lifelong severe-CR experiment, but the careful CALERIE trial put non-obese adults on sustained moderate restriction for two years and found real benefits — improved cardiovascular and metabolic markers, less inflammation, and (in a lovely connection to Chapter 2) an actual slowing of the DunedinPACE pace-of-aging clock. But the honest framing is sober: the effects were meaningful but modest, severe restriction is genuinely hard to sustain and carries its own costs (loss of bone and muscle, cold intolerance, and a quality-of-life toll most people will not accept), and we have no human evidence that CR extends maximum lifespan. CR is the real thing, and it is also not a magic wand — which is precisely why so much effort has gone into finding a drug that delivers its benefits without the hunger.

Deeper Water — the sensors read ratios, not amounts. There is an elegant design principle hiding in how these nutrient sensors actually work, and it’s worth seeing. AMPK does not measure how much fuel the cell has in absolute terms; it reads a ratio — roughly the amount of AMP (the spent, low-energy form of the cell’s energy currency) relative to ATP (the charged form). When the cell burns through fuel, ATP falls and AMP rises, so the AMP-to-ATP ratio climbs, and AMPK fires in proportion. Sirtuins, likewise, are tuned to the ratio of NAD⁺ to NADH — a readout of how oxidized-versus-reduced, how fed-versus-fasted, the cell’s metabolism currently is. Why ratios? Because a ratio is a far more robust signal than an absolute concentration. The total amount of any metabolite swings with cell volume, dilution, and the size of the metabolite pool; a ratio of two related molecules cancels all of that out and reports the cell’s underlying state — its energy charge, its redox balance — independent of how big or dilute the cell happens to be. Evolution built fuel gauges that read a normalized quantity, for the same reason a good instrument reports a ratio rather than a raw reading: it’s the quantity that actually means something. This matters for the rest of the chapter, because it tells you what it would take to fool a sensor. To make a cell think it’s fasting, you don’t necessarily starve it — you shift one of these ratios. That is the entire premise of the molecules we turn to now, and it’s also why they’re so easy to oversell: moving the ratio is straightforward, but moving the ratio is not the same as making the animal younger. Hold that thought; it’s about to become the whole problem. (One more human footnote: the worm’s daf-16 corresponds to the human FOXO genes, and a particular variant of FOXO3 is among the most reliably replicated genetic associations with reaching extreme old age — the worm’s longevity switch is, faintly, still visible in which humans become centenarians.)

The most oversold molecule

Now we arrive at the part of aging biology where the gap between what is claimed and what is known is the widest in the entire field — and the chapter has spent four sections building the tools you need to see it clearly. The science underneath is real and serious. The marketing on top of it is not. Both facts are true at once, and keeping them apart is the whole skill.

Start with the legitimate science. In the late 1990s, Leonard Guarente’s lab at MIT found that a gene called Sir2 extended lifespan in yeast, and that its activity depended on NAD⁺ — the same energy-state molecule from the box above. This was genuinely exciting: here was a longevity-promoting enzyme (a sirtuin) directly wired to the cell’s metabolic state through NAD⁺. The logic that followed was clean and seductive: sirtuins promote longevity; sirtuins run on NAD⁺; NAD⁺ levels decline with age; therefore, restore NAD⁺ (or activate sirtuins directly) and you might slow aging. An entire industry grew out of that syllogism. But notice that it is a chain of “mights,” and a chain is only as strong as its weakest link.

The first attempt to exploit it became a cautionary tale that everyone in this field should know by heart. In 2003, a compound was reported to activate the sirtuin SIRT1 and extend lifespan in yeast — and that compound was resveratrol, the molecule in red wine. The story wrote itself: the longevity secret of red wine, a natural compound that switches on your anti-aging enzymes. Follow-up work reported that resveratrol improved the health of mice on junk-food diets. A company, Sirtris, was founded to develop sirtuin activators, and in 2008 the pharmaceutical giant GSK bought it for roughly 720 million dollars. Red-wine longevity was, briefly, one of the hottest ideas in medicine.

Then it came apart. Independent laboratories — including ones at major drug companies — could not reproduce the central claim that resveratrol directly activates SIRT1. The apparent activation turned out to be, in significant part, an artifact of the assay: resveratrol only “activated” SIRT1 when the test used an unnatural, fluorescently-tagged substrate; with the enzyme’s real targets, the effect largely vanished. The dramatic lifespan claims in animals did not robustly hold up either. In 2013, GSK shut Sirtris down. Resveratrol today is regarded, at best, as a weak and inconsistent intervention, and the episode stands as a textbook case of how an exciting result, a measurement artifact, and several hundred million commercial dollars can combine to outrun the evidence by years.

All 10 chapters of Will you live to 120? · Foundations · All courses